IL6 and arthritic joint disease: Reduction in arthritis was accompanied by reduced levels of IL‐6 (Figure 3A) and the inflammatory marker alpha‐1‐acid glycoprotein in sera of animals treated with the TLR9 antagonist (Figure 3B).